While most people don’t choose a healthcare career to drive profits, many soon realize that it’s impossible to support high-quality care without having a clear understanding of the financial realities of the business. This…
Continue Reading
McKinsey estimates that digital health solutions could cut global healthcare costs by $3 trillion per year by 2030. But we’ll only hit that number if people actually use the digital health solutions we build…
Continue Reading
With the Inflation Reduction Act now on the books, the U.S. Centers for Medicare & Medicaid Services (CMS) will begin negotiating drug prices with the pharmaceutical industry. That, combined with other headwinds such as increased competition from me-too drugs, and ever-present pricing pressure from payers, means that pharma players now more than ever need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Learning from the auto industry Almost every industry has had to confront a fundamental existential question: What is our product? Consider the automotive industry, which once was largely about hardware…
![How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]](https://i0.wp.com/www.mediformatica.com/wp-content/uploads/2023/02/how-to-leverage-diagnostic-development-to-guard-against-rsv-flu-and-covid-19-sponsored.jpg?fit=600%2C349&ssl=1)
For the first two years of the Covid-19 pandemic, healthcare professionals focused on understanding the Covid-19 virus, how best to guard against it, and developing tests to detect it. They also tracked, aggregated, and analyzed health data to assess and monitor the public health threat on a regional, state and country-wide level. In the longer term, vaccine development and distribution were used to slow the spread to avoid a collapse of the health system and to reduce the potency of the virus for the majority of people.
More recently, attention has shifted to the long perceived threat of viruses coming together with…
To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one in five deaths in 2020 in theUnited States.
Even minimally invasive pulmonary artery banding — a surgical technique that has been in use since Harry Truman was president — requires access to the chest cavity. A new treatment under development by HeartPoint Global seeks to provide a minimally invasive alternative to current treatments for pulmonary arterial hypertension associated with Congenital Heart Disease.A device delivered through the leg would cost only…
